
What You Should Know
- Predictive pharmaceutical commercial intelligence company ODAIA raises $15M Series C financing round led by Monograph Capital and anchored by strategic investor PHM, the leading U.S. health media agency and part of Publicis Groupe.
- Returning institutional investors participating in the Series C include Series A backers BDC Capital, Flint Capital, Innospark Ventures, and Graphite Ventures, alongside Series B investors Threshold Ventures and Wittington Ventures.
- Alongside the equity investment, ODAIA executed a commercial Platform Agreement naming PHM as its exclusive agency partner in the United States to connect digital media activation with field sales coordination across pharmaceutical brands.
- ODAIA’s commercial intelligence platform addresses data fragmentation inside biopharmaceutical enterprises—where brand, marketing, and field teams operate from disconnected views of the same healthcare professional (HCP)—by unifying prescribing telemetry, field sales activity, and digital engagement into a single HCP record.
Portfolio-Scale Omnichannel Architecture: Brand Strategy Studio, Field Intelligence, and Marketing Intelligence
ODAIA’s platform establishes a unified commercial intelligence foundation that integrates disparate prescribing data, field sales activity, and digital engagement signals into a single longitudinal view of each physician. Rather than requiring data science teams to rebuild models for every product launch, brand leaders codify commercial objectives once inside Brand Strategy Studio, allowing ODAIA’s decision engines to translate that strategy into physician-level execution across therapeutic areas through configuration rather than custom engineering.
Using predictive machine learning to analyze patient journey trajectories, the platform identifies physicians whose patient panels are likely to require a specific therapy—often months before formal diagnoses appear in standard claims or electronic health record feeds. That intelligence flows simultaneously into two operational layers: Field Intelligence delivers prioritized, dynamic call plans directly into field representatives’ existing CRM workflows, while Marketing Intelligence orchestrates individualized, sequenced HCP journeys across digital media and partner channels. Every recommendation surfaces transparent underlying reasoning for commercial and medical-legal-regulatory compliance teams, supports natural-language querying by commercial executives, and continuously measures engagement and prescription lift to recalibrate future actions.

